Anika Therapeutics, Inc. Reports Material Event

Anika Therapeutics (ANIK) filed an 8‑K noting it furnished a press release with its financial results for the third quarter ended September 30, 2025.

Accepted by SEC EDGAR 11/05/2025 - 07:20 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Anika Therapeutics (ANIK) filed an 8‑K noting it furnished a press release with its financial results for the third quarter ended September 30, 2025. The company states this information is being furnished, not filed, under the Exchange Act. The earnings press release is attached as Exhibit 99.1.

Anika also announced a regulatory milestone for Hyalofast. The company filed the third and final module of its Premarket Approval application for Hyalofast, a resorbable, hyaluronic acid‑based scaffold used with autologous bone marrow aspirate concentrate to treat articular cartilage defects in the knee, and reported results from its U.S. pivotal Phase III FastTRACK trial evaluating Hyalofast. This update is provided via a separate press release attached as Exhibit 99.2.

Insights

Regulatory affairs analyst

Administrative 8‑K with earnings furnish and PMA progress; neutral impact.

Anika Therapeutics furnished Q3 results via Item 2.02, which does not carry Section 18 liability. This is a standard disclosure approach for quarterly press releases and typically does not, by itself, alter fundamentals.

Under Item 8.01, Anika filed the third and final module of its PMA for Hyalofast and reported Phase III FastTRACK trial results. Completing the PMA modules is a key procedural step before an FDA decision, but outcomes and timing are not stated in the excerpt.

Investor attention may focus on FDA review status once accepted; subsequent disclosures could detail review milestones or advisory committee needs, if any.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

False000089843700008984372025-11-052025-11-05iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  November 5, 2025

_______________________________

Anika Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-14027	04-3145961
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

32 Wiggins Avenue

Bedford, Massachusetts 01730

(Address of Principal Executive Offices) (Zip Code)

(781) 457-9000

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	ANIK	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

The following information, including the exhibit attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

On November 5, 2025, Anika Therapeutics, Inc. (“Anika”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 8.01. Other Events.

On November 5, 2025, Anika also issued a press release announcing that it filed the third and final module of its Premarket Approval application for Hyalofast, its resorbable, hyaluronic acid-based scaffold used with autologous bone marrow aspirate concentrate for treating articular cartilage defects in the knee, and reporting results from its U.S. pivotal Phase III FastTRACK clinical trial evaluating Hyalofast (the “Press Release”). A copy of the Press Release is attached hereto as Exhibit 99.2 and is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release of Anika Therapeutics, Inc. dated November 5, 2025, furnished herewith.
99.2		Press Release of Anika Therapeutics, Inc. dated November 5, 2025, filed herewith.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Anika Therapeutics, Inc.
Date: November 5, 2025	By:	/s/ Cheryl R. Blanchard
		Cheryl R. Blanchard
		President and Chief Executive Officer